RxDoctor Payments Data

Elinor Zhou, MD

Internal Medicine · Baltimore, MDNPI 1275952921

Payments from drug & device makers

$2,722in general payments, 2019–2025

Across 112 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$967
  • Takeda Pharmaceuticals U.S.A., Inc.$313
  • Johnson & Johnson$273
  • Ardelyx, Inc.$146
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$145
  • Ferring Pharmaceuticals Inc.$115
  • plus $763 from 18 others

What the payments were for

  • Food & beverage$2,722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,722 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$134,651
Medicare patients
472
Services billed
1,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide36$39,675
CreonLipase/Protease/Amylase18$21,552
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates141$8,299
Dexlansoprazole DrDexlansoprazole18$5,807
Esomeprazole Magnesium83$3,616
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,195
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl123$1,755
Pantoprazole Sodium86$1,609
Omeprazole124$1,368
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl55$1,085
Famotidine50$739
CholestyramineCholestyramine (With Sugar)12$701
Dicyclomine Hcl16$367
Sucralfate11$203
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl12$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$967$61,22754 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →